State-Backed Capital Inflates Chinese Neurotech Valuations as Shanghai Unicorn Files for Insolvent Star Market Listing

China’s aggressive, state-directed campaign to establish global dominance in frontier biotechnology has hit the public markets, exposing the raw financial strains of a sector heavily insulated from standard commercial metrics. Neuracle Technology (Shanghai) Co.,…

Source